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ABSTRACT 
OBJECTIVES. To analyse the influence of geolocation and ethnicity on the clinical 
presentation of primary Sjögren syndrome (SjS) at diagnosis. 
METHODS. The Big Data Sjögren Project Consortium is an international, multicentre 
registry designed in 2014. By January 2016, 20 centres from five continents were 
participating. Multivariable logistic regression analyses were performed. 
RESULTS. We included 7748 (93%) women and 562 (7%) men, with a mean age at 
diagnosis of primary SjS of 53 years. Ethnicity data was available for 7884 (95%) 
patients: 6174 (78%) patients were White, 1066 (14%) Asian, 393 (5%) Hispanic, 104 
(1%) Black/African American and 147 (2%) had other ethnicities. SjS was diagnosed a 
mean of 7 years earlier in Black/African American  compared with White patients, the 
female:male ratio was highest in Asian patients (27:1) and lowest in Black/African 
American  patients (7:1); the prevalence of sicca symptoms was lowest in Asian 
patients; a higher frequency of positive salivary biopsy was found in Hispanic and 
White patients. A north-south gradient was found with respect to a lower frequency of 
ocular involvement in northern countries for dry eyes and abnormal ocular tests in 
Europe (OR 0.46 and 0.44, respectively) and Asia (OR 0.18 and 0.49,respectively) 
compared with southern countries. Higher frequencies of ANA were reported in 
northern countries in America (OR=1.48) and Asia (OR=3.80) while, in Europe, northern 
countries had lowest frequencies of ANA (OR=0.67) and Ro/La (OR=0.69). 
CONCLUSIONS. This study provides the first evidence of a strong influence of 
geolocation and ethnicity on the phenotype of primary SjS at diagnosis. 
  
KEY WORDS: primary Sjögren syndrome, ethnicity, geoepidemiology, salivary gland 
biopsy, Ro/La autoantibodies 
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INTRODUCTION 
Primary Sjögren syndrome (SjS) is a systemic autoimmune disease that mainly targets 
the exocrine glands, leading to dryness of the main mucosal surfaces.[1] The 
histological hallmark is focal lymphocytic infiltration of the targeted organs, and the 
key immunological markers include ANA (the most frequently detected), anti-Ro/SjS-A 
(the most specific) and cryoglobulins and hypocomplementaemia (the main prognostic 
markers).[1] SjS overwhelmingly affects middle-aged women, and its frequency varies 
widely according to study designs and the classification criteria used. More recent 
studies using the 2002 American-European classification criteria[2] have reported an 
incidence of 3-11 cases per 100,000 persons and a prevalence of between 0.01 and 
0.72%.[3,4] 
The influence of ethnicity on the phenotypic expression of systemic autoimmune 
diseases has been suggested by various studies, especially in systemic lupus 
erythematosus (SLE), which has been reported as being more frequent and having less 
favourable outcomes in non-White populations.[5,6] With respect to the influence of 
geographical factors, a potential north-south gradient in the frequency of autoimmune 
diseases has been suggested.[7,8] In primary SjS, there is no information on the 
influence of ethnicity or geolocation on the phenotypic expression of the disease. Only 
one recent study, in the general population of Greater Paris,[4] has evaluated the 
influence of ethnicity on the frequency of primary SjS, and this found a two-fold higher 
prevalence in patients with non-European backgrounds compared with those with a 
European background.  
The objective of this study was to determine the influence of geolocation and ethnicity 
on the clinical presentation of primary SjS at diagnosis in a large international cohort of 
patients. 
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METHODS 
Patients 
The Big Data Sjögren Project Consortium is an international, multicentre registry 
designed in 2014 to take a “high-definition” picture of the main features of primary SjS 
at diagnosis by merging international SjS databases. International experts from the 
EULAR-SjS Task Force were invited to participate. Inclusion criteria were the fulfilment 
of the 2002 classification criteria.[2]; in addition, a letter was sent to the corresponding 
authors of manuscripts published in the last two years in Pubmed that included clinical 
data on at least 50 patients with primary SjS, inviting them to join the study.  Exclusion 
criteria for considering SjS as a primary disease were chronic HCV/HIV infections, 
previous lymphoproliferative processes, and associated systemic autoimmune 
diseases. Diagnostic tests for SjS (ocular tests, oral tests and salivary gland biopsy) 
were carried out according to the recommendations of the European Community 
Study Group.[9] The study was approved by the Ethics Committee of the Coordinating 
Centre (Hospital Clinic, Barcelona, Spain, registry HCB/2015/0869). 
Disease diagnosis was defined as the time when the attending physician confirmed 
fulfilment of the 2002 criteria. At this time, the main features of the disease were 
retrospectively collected and analysed (age, gender, ethnicity, country of residence, 
fulfilment of the 2002 criteria items, antinuclear antibodies, rheumatoid factor, C3 and 
C4 levels, and cryoglobulins). By January 2016, the participant centres had included 
8417 patients from 20 countries in five continents. Further confirmation was made by  
excluding cases in which fulfilment of the 2002 criteria could not be directly ensured 
according to the data provided (lack of information about items IV and VI – salivary 
biopsy and Ro/La autoantibodies).  
Patients were classified according to the geolocation of the country of the diagnosing 
hospital. Patients were first classified by continent, with an additional north-south sub-
classification according to latitude in continents including patients from > 1 country;  
the subclassification of the latitudes is not standard and was adapted to the 
geolocation of the countries included in the registry: latitude > or < 50’N in Europe, 
equator > or < in America and latitude > or < 30’N in Asia). Ethnicity was classified 
retrospectively (asking the patient or relatives if necessary) according to the OMB 
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Standards for Maintaining, Collecting, and Presenting Federal Data on Race and 
Ethnicity of the FDA,[10] using the following categories and definitions: 
- Asian. A person having origins in any of the original peoples of the Far East, 
Southeast Asia, or the Indian subcontinent, including, for example, Cambodia, 
China, India, Japan, Korea, Malaysia, Pakistan, the Philippine Islands, Thailand, 
and Vietnam. 
- Black or African American. A person having origins in any of the black racial 
groups of Africa. 
- Hispanic or Latino. A person of Cuban, Mexican, Puerto Rican, South or Central 
American, or other Spanish culture or origin, regardless of race. However, 
Spanish patients from Spain were included in the White definition. 
- White. A person having origins in any of the original peoples of Europe, the 
Middle East, or North Africa. 
- Others. Native Hawaiian or Other Pacific Islander; defined as a person having 
origins in any of the original peoples of Hawaii, Guam, Samoa, or other Pacific 
Islands; American Indian or Alaska Native, defined as a person having origins in 
any of the original peoples of North and South America (including Central 
America), and who maintains tribal affiliation or community attachment; and 
patients with one or more racial designations. 
 
Statistical analysis  
Descriptive data are presented as mean and standard deviation (SD) for continuous 
variables and numbers and percentages (%) for categorical variables. The prevalence of 
a specific feature is stated as the number of cases with that feature/number of cases in 
which the feature was detailed. The Chi-square test was used to study categorical 
features at diagnosis according to geolocation (continent) and ethnic groups. One-way 
ANOVA tests were used to compare the mean age at diagnosis. The following sub-
analyses were made: i) geolocation of countries by latitude (north vs. south) in Europe 
(latitude > or < 50’N), America (equator ><) and Asia (latitude > or < 30’N); ii) Asian 
patients and country of residence (Asian vs. non-Asian countries); iii) Hispanic patients 
and country of residence (Latin American vs. other countries). Clustered bar charts 
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were constructed to compare ethnic clusters according to fulfilment of the 2002 
criteria items and the baseline immunological profile.[11] P-values were adjusted for 
multiple comparisons using the false discovery rate (FDR) correction.[12] Multivariable 
logistic regression analyses adjusted for ethnicity, age at diagnosis and gender were 
performed to study the association between geolocation with diagnostic tests for SjS 
and immunological markers at diagnosis. To handle missing data due to non-evaluated 
diagnostic tests for SjS or non-performed immunological markers, “available case 
analysis” was assumed for the comparisons according to geolocation and ethnic 
groups. The missing data pattern shows that most variables had low percentages of 
missing data (see online supplementary Figure S1). All significance tests were two-
tailed and values of p < 0.05 were considered significant. P-values were adjusted for 
multiple comparisons using the false discovery rate (FDR) correction. All analyses were 
conducted using the R V.3.2.3 for Windows statistical software package 
(https://www.R-project.org/.). 
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RESULTS 
a) Baseline characterization 
Of the 8417 patients originally included in the database, 107 were excluded in the 
refinement process (lack of information about items IV and/or VI). The baseline 
characteristics of the final cohort (8310 patients) are summarized in Table 1. The 
cohort included 7748 (93%) women and 562 (7%) men (female: male ratio, 14:1), with 
a mean age at diagnosis of primary SjS of 53.2 (SD 14.2) years. The frequencies of 
fulfilment of the 2002 classification criteria items were 92% for dry eye (item I), 93% 
for dry mouth (item II), 86% for abnormal ocular tests (item III), 89% for positive minor 
salivary gland biopsy (item IV), 80% for abnormal oral diagnostic tests (item V) and 75% 
for positive anti-Ro/La antibodies (item VI). The frequency of immunological markers 
at diagnosis was: positive ANA in 81% of patients, positive RF in 49%, low C3 levels in 
14%, low C4 levels in 13% and positive serum cryoglobulins in 7.5% of patients. 
 
b) Geolocation 
The main results on geolocation (continent and subareas classified by latitude) are 
summarized in Table 1. Patients came mainly from Europe (n=6045), America (n=1134) 
and Asia (n=940) (see online supplementary Table S1). Table 2 compares the main 
geolocational features classified according to latitude in these three continents. 
Logistic regression analysis adjusted by ethnicity, age at diagnosis and gender showed 
that northern European patients  (latitude > 50´N) had a lower frequency of ocular 
dryness (OR 0.46, 95%CI 0.37 to 0.57), abnormal ocular tests (OR 0.44, 95%CI 0.37 to 
0.53), ANA (OR 0.67, 95%CI 0.58 to 0.78), low C3 levels (OR 0.76, 95%CI 0.62 to 0.93) 
and Ro/La autoantibodies (OR 0.69, 95%CI 0.60 to 0.79) and a higher frequency of 
abnormal oral tests (OR 2.12, 95%CI 1.71 to 2.64) and RF (OR 1.62, 95%CI 1.41 to 1.86) 
compared with southern European patients. North American patients had a lower 
frequency of positive salivary biopsy (OR 0.44, 95%CI 0.20 to 0.88), and a higher 
frequency of ANA (OR 1.48, 95%CI 1.05 to 2.09), RF (OR 2.04, 95%CI 1.49 to 2.82), 
Ro/La autoantibodies (OR 4.10, 95%CI 2.93 to 5.78) and low C4 levels (OR 6.94, 95%CI 
3.17 to 18.32) compared with South American patients. Northern Asian patients had a 
lower frequency of dry mouth (OR 0.30, 95%CI 0.19 to 0.46), dry eyes (OR 0.18, 95%CI 
0.12 to 0.28), abnormal ocular tests (OR 0.49, 95%CI 0.30 to 0.79) and positive salivary 
9 
 
biopsy (OR 0.42, 95%CI 0.26 to 0.68), and a higher frequency of ANA (OR 3.80, 95%CI 
2.54 to 5.73) and Ro/La autoantibodies (OR 2.78, 95%CI 1.89 to 4.09), compared with 
southern Asian patients. 
 
c) Ethnicity 
Ethnicity data was available for 7884 (95%) patients of the total cohort: 6174 (78.3%) 
patients were classified as White, 1066 (13.5 %) as Asian, 393 (5%) as Hispanic, 104 
(1.3%) as Black/African American patients and 147 (1.9%) as other ethnicities (Table 1). 
Patients from European centres were overwhelmingly White compared with those 
from American centres (96% vs. 52%, p<0.001); Supplementary Table S2 summarizes 
the main features of White patients compared with patients of other ethnicities. Table 
3 shows the main features at presentation according to ethnicity: the highest 
percentage of males was in Black/African American  patients and the lowest in Asian 
patients; the youngest age at diagnosis was in Black/African American  patients and 
the oldest in White patients; the lowest frequency of sicca symptoms was in Asian 
patients and the highest in other ethnicities; the lowest frequency of abnormal 
diagnostic tests was in patients of other ethnicities and the highest in Hispanic 
patients; and the highest frequency of Ro/La autoantibodies was in Asian patients and 
the lowest in patients of other ethnicities. Figure 1 includes clustered bar charts for the 
percentage of fulfilment of the six items of the 2002 classification criteria, and Figure 2 
the percentage of abnormal results in the immunological profile according to ethnicity. 
The potential effect of geolocation in patients classified in the same ethnic group was 
analysed in two sub-studies. Asian patients diagnosed in non-Asian countries had a 
higher frequency of dry mouth (p=0.007) and dry eye (p=0.003) compared with native 
patients (see online supplementary Figure S2). Hispanic patients living outside Latin 
American countries had a lower frequency of abnormal salivary biopsy (p=0.001) and 
positive RF (p=0.008), and a higher frequency of low C3 levels (p<0.001) compared 
with native patients (see online supplementary Figure S3). 
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DISCUSSION 
The etiopathogenesis of primary SjS is unknown. The most frequently proposed 
hypothesis is based on the effect of multiple, mainly unknown, environmental factors 
affecting an individual with a specific genetic susceptibility. Geoepidemiological and 
ethnic studies may help elucidate the complex combination of genes and environment 
in systemic autoimmune diseases.[7] The most relevant studies have been carried out 
in SLE: US studies have reported a 2-3-fold higher incidence and prevalence of disease 
rates in African American patients, UK studies up to 8-fold higher rates in Afro-
Caribbean and Asian patients, and other studies have found higher prevalences in 
Native American Indians, Pacific People and Aborigines compared with European 
populations.[13] In systemic sclerosis, geoepidemiological studies have revealed a 
higher frequency in the US and Australia than in Europe and Asia,[7] while in primary 
SjS, a two-fold higher prevalence in patients with non-European backgrounds has 
recently been reported.[4] 
Ethnicity also influences the phenotypic expression of autoimmune diseases, including 
the clinical course and outcomes. In SLE, the LUMINA project (Lupus in Minorities: 
Nature versus Nurture) found that African American and Hispanic American SLE 
patients tend to develop the disease earlier and present with more-severe disease.[14] 
In systemic sclerosis, a higher mortality rate has been reported in African American 
populations compared with White populations,[7] while in systemic vasculitis, non-
European patients with ANCA-vasculitis also showed more severe disease and higher 
damage scores.[15] 
Until now, no studies have focused on the influence of geoepidemiology and ethnicity 
on the phenotypic expression of primary SjS. We evaluated these factors in the largest 
reported series of patients with primary SjS fulfilling the 2002 criteria from 20 
countries across five continents. We found significant variations between ethnic 
groups. The disease was diagnosed a mean of seven years earlier in Black/African 
American  patients compared with White patients, a trend also reported by Maldini et 
al. in the Parisian multi-ethnic cohort.[4] The female: male ratio also varied 
significantly, with the highest ratio (27:1) in Asian patients and the lowest (7:1) in 
Black/African American  patients. The prevalence of sicca symptoms at diagnosis also 
varied significantly: the lowest frequencies were in Asian patients, a finding that has 
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been related to cultural differences in previous studies.[16]  
This is the first study to analyse the influence of ethnicity on the results of SjS 
diagnostic tests included in the current classification criteria. Hispanic patients had the 
highest rates of abnormal results and higher frequencies of subjective dryness 
symptoms. In contrast, patients of other ethnicities had the lowest rates of abnormal 
results but higher frequencies of sicca symptoms. This might suggest that ethnicity 
may influence the results of the objective diagnostic tests for dry eyes and mouth in 
primary SjS patients, with Hispanic and White patients being more likely to have 
abnormal results compared with other ethnicities. With respect to the frequency of 
fulfilment of the histopathological criteria (salivary biopsy showing Chisholm-Mason 
grade 3 or 4), we found a pattern of ethnic association similar to that observed for 
objective tests for dryness, with a higher frequency of positive salivary biopsy in 
Hispanic and White patients compared with the other ethnicities; Maldini et al.[4] 
reported a similar, although not significant, trend in the multi-ethnic Paris cohort. 
The influence of ethnicity on the phenotypic expression of primary SjS at diagnosis 
could be driven by immunogenetic differences. Maldini et al.[4] found a younger age at 
diagnosis and an increased frequency of polyclonal hypergammaglobulinaemia and 
positive Ro/La antibodies in non-European patients, a reasonable association since 
immunopositive SjS patients are often diagnosed earlier.[17] We have confirmed this 
association: patients from ethnic groups with the highest frequencies of positive anti-
Ro antibodies (Asian, Hispanic and Black/African American ) also had the youngest ages 
at diagnosis; a similar trend was observed for anti-La antibodies, except for 
Black/African American  patients, who had the second-lowest frequency of all ethnic 
groups. Ro/La immunogenicity has traditionally been linked with genetic factors, 
mainly with specific HLA class II alleles,[18] and a joint contribution of HLA-DR and DQ 
alleles has been suggested as relevant for the development of antibodies against Ro/La 
autoantigens.[19] Most SjS patients share a common allele (DQA1*0501) across racial 
and ethnic boundaries.[20] However, Kang et al.[21] found significant differences in 
the frequency of some HLA-DR haplotypes (a higher frequency of DRB3 in Caucasians 
and DRB4 in Japanese, and a lower frequency of DPB1 in Chinese patients). Future 
immunogenetic studies in primary SjS should evaluate the influence of ethnicity on the 
results, searching for possible immunogenetic differences. 
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A potential north-south autoimmune gradient, with rates seeming to increase 
according to distance from the Equator, has been suggested in the prevalence and 
incidence of several autoimmune diseases including type 1 diabetes mellitus, multiple 
sclerosis, and inflammatory bowel disease.[7,22-25] Little  geoepidemiological data is 
available for systemic autoimmune diseases, and there are no data on primary SjS. The 
present study found some interesting results after comparing northern vs. southern 
countries in the three continents for which data from more than one country are 
available (Europe, America and Asia). A north-south gradient was confirmed with 
respect to a lower frequency of ocular involvement and a higher frequency of 
cryoglobulinemic-related tests (cryoglobulins and hypocomplementaemia) in northern 
compared with southern countries. The gradient was different in Europe with respect 
to the other components of primary SjS. For salivary gland involvement, the highest 
rates of abnormal results (including biopsy) in Europe were found in patients from 
northern countries, while in America and Asia the highest rates were reported in 
patients from southern countries. A similar gradient was observed with respect to 
autoantibodies (ANA, Ro, La): the highest frequencies in America and Asia were 
reported in northern countries while in Europe, the highest frequencies were reported 
in southern countries. These results suggest, for the first time, that geolocation may 
influence the phenotypic expression of primary SjS at diagnosis, including significant 
geoepidemiological variations in the prevalence of dryness, the frequency of abnormal 
diagnostic tests and the positivity of the main immunological markers. 
We also analysed the influence of geoepidemiological migration on the phenotypic 
expression of primary SjS at diagnosis by comparing ethnic migrant and native 
populations. Interestingly, Asian patients diagnosed with primary SjS in non-Asian 
countries (overwhelmingly in Europe and the US) had a higher frequency of sicca 
symptoms than Asian patients diagnosed in Asian countries. With respect to Hispanic 
patients diagnosed outside Latin America, differences were found in diagnostic tests, 
with a lower frequency of positive salivary biopsy, a lower frequency of positive RF and 
a higher frequency of low C3 values. No other studies have analysed this, although the 
study by Maldini et al.[4] reported a differing clinical and immunological pattern of SjS 
expression in French patients with a non-European background. 
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The results, however, should be interpreted with caution, and some limitations should 
be pointed out. Large studies may detect some differences which, although statistically 
significant, may not be relevant clinically, with further studies being necessary to 
confirm their clinical relevance. In addition, the predominant presence of European 
patients (due to the origin of the project in the EULAR SS Group) could limit the 
generalization of the results, due to the small size of some ethnic subpopulations, such 
as Black African American patients. With respect to the study design, although studies 
comparing relative frequencies of clinical features should, ideally, be population based,  
our study was designed according to a “Data Sharing” approach, which is currently 
considered an alternative way of international scientific collaboration, especially in 
diseases with a low prevalence [27]. Since the participant centers are mainly tertiary 
university centers that are considered the referral center in their corresponding cities 
(and in most cases, in their countries), the magnitude of the selection bias may vary 
between the 20 countries involved in the study and this could have an impact on the 
results (Supplementary Figure S4 summarizes the size of each cohort classified per 
city), as may differing medical practices across regions (availability of diagnostic tests 
included in the 2002 criteria); in fact, we found a negative correlation between the 
percentage of biopsied patients and the percentage of Ro/La positive patients in each 
center (R = -0.55) (Supplementary Figure S5). Other sources of heterogeneity may 
include the assays used by the different centers, although all are commercial tests and 
more than 80% used the same technique (ELISA) to test for Ro/La autoantibodies and 
ANA were overwhelmingly (>95%) tested for by indirect immunofluorescence), and the 
missing data for some variables (Supplementary Figure S1). 
In summary, this study provides the first evidence for a strong influence of geolocation 
and ethnicity on the phenotype of primary SjS at diagnosis. Genetic and environmental 
factors probably contribute to phenotypic variance in SjS, and a recent study has 
attributed 54% of the predisposition to developing the disease to familial transmission 
(heritability plus shared environmental factors) and 46% to non-shared environmental 
factors.[26] Geoepidemiology and ethnicity should be considered as key variables that 
should be analysed in multi-ethnic studies of patients with primary SjS. 
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Hospital, China); C. Baldini (Rheumatology Unit, University of Pisa, Pisa, Italy); J.E. Gottenberg (Department of 
Rheumatology, Strasbourg University Hospital, Université de Strasbourg, CNRS, Strasbourg, France); D. Danda, P. 
Sandhya (Department of Clinical Immunology & Rheumatology, Christian Medical College & Hospital, Vellore, India); 
L. Quartuccio, L. Corazza, S De Vita (Clinic of Rheumatology, Department of Medical and Biological Sciences, 
University Hospital "Santa Maria della Misericordia", Udine, Italy);  R. Priori, E. Bartoloni (Department of Internal 
Medicine and Medical Specialties, Rheumatology Clinic, Sapienza University of Rome, Italy); G. Hernandez-Molina, J. 
Sánchez-Guerrero (Immunology and Rheumatology Department, Instituto Nacional de Ciencias Médicas y Nutrición 
Salvador Zubirán. México City, Mexico); A.A. Kruize, E. van der Heijden (Department of Rheumatology and Clinical 
Immunology, University Medical Center Utrecht, Utrecht, The Netherlands); V. Valim (Department of Medicine, 
Federal University of Espírito Santo, Vitória, Brazil); M. Kvarnstrom, M. Wahren-Herlenius (Department of Medicine, 
Solna, Unit of Experimental Rheumatology, Karolinska Institutet, and Karolinska University Hospital, Stockholm); D. 
Sene (Service de Médecine Interne 2, Hôpital Lariboisière, Université Paris VII, Assistance Publique-Hôpitaux de 
Paris, 2, Paris, France); R. Gerli (Rheumatology Unit, Department of Medicine, University of Perugia, Italy); S. 
Praprotnik (Department of Rheumatology, University Medical Centre, Ljubljana, Slovenia); D. Isenberg (Centre for 
Rheumatology, Division of Medicine , University College London , UK); R. Solans (Department of Internal Medicine, 
Hospital Vall d'Hebron, Barcelona, Spain); M. Rischmueller, S. Downie-Doyle (Department of Rheumatology, School 
of Medicine, The University of Western Australia, Crawley, Australia); S-K. Kwok, S-H. Park (Seoul St. Mary's Hospital, 
The Catholic University of Korea, Seoul); G. Nordmark (Rheumatology, Department of Medical Sciences, Uppsala 
University, Uppsala, Sweden); Y. Suzuki, M. Kawano (Division of Rheumatology , Kanazawa University Hospital , 
Kanazawa , Ishikawa , Japan); R. Giacomelli, F. Carubbi (Clinical Unit of Rheumatology, University of l'Aquila, School 
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of Medicine, L'Aquila, Italy); V. Devauchelle-Pensec, A. Saraux (Rheumatology Department, Brest University 
Hospital, Brest, France); M. Bombardieri, E. Astorri (Centre for Experimental Medicine and Rheumatology, Queen 
Mary University of London, UK); B. Hofauer (Hals-Nasen-Ohrenklinik und Poliklinik, Technische Universität 
München, München, Germany); H. Bootsma, A. Vissink (Department of Rheumatology & Clinical Immunology, 
University of Groningen, University Medical Center Groningen, the Netherlands); J.G. Brun, D. Hammenfors 
(Department of Rheumatology, Haukeland University Hospital, Bergen, Norway); G. Fraile (Department of Internal 
Medicine, Hospital Ramón y Cajal, Madrid, Spain); S. E. Carsons (Division of Rheumatology, Allergy and Immunology 
Winthrop-University Hospital, Stony Brook University School of Medicine, Mineola, NY, USA); T. A. Gheita, 
(Rheumatology Department, Kasr Al Ainy School of Medicine, Cairo University, Egypt); H.M. Khalil 
(Ophthalmology Department, Faculty of Medicine, Beni Suef University, Egypt); J. Morel (Department of 
Rheumatology, Teaching hospital and University of Montpellier, Montpellier, France); C. Vollenveider (German 
Hospital, Buenos Aires, Argentina); F. Atzeni (IRCCS Galeazzi Orthopedic Institute, Milan, Italy); S. Retamozo 
(Hospital Privado Universitario de Córdoba, Institute University of Biomedical Sciences University of Córdoba, 
Córdoba, Argentina; V. Moça Trevisano (Federal University of São Paulo, Sao Paulo, Brazil); B. Kostov, A. Sisó-
Almirall (Primary Care Research Group, IDIBAPS, Centre d’Assistència Primària ABS Les Corts, CAPSE, Barcelona, 
Spain). 
 
b) Members of the French ASSESS Cohort 
J. Sibilia (Rheumatology Centre National de Référence des Maladies Auto-Immunes Rares, Institut National de la 
Santé et de la Recherche Médicale UMRS_1109, Fédération de Médecine Translationnelle de Strasbourg, Strasbourg 
University Hospital, Université de Strasbourg, Strasbourg, France); C. Miceli-Richard, G. Nocturne (Rheumatology, 
Bicetre Hospital, Institut National de la Santé et de la Recherche Médicale U-1012, Université Paris Sud, Assistance 
Publique des Hôpitaux de Paris, Paris, France); J. Benessiano (Centre de Ressources Biologiques, Bichat Hospital, 
Assistance Publique des Hôpitaux de Paris, Paris, France); P. Dieude (Rheumatology, Bichat Hospital, Assistance 
Publique des Hôpitaux de Paris, Paris, France); J-J. Dubost (Rheumatology, Clermont-Ferrand Hospital, Clermont-
Ferrand, France); A-L. Fauchais (Internal Medicine, Limoges Hospital, Limoges, France); V. Goeb (Rheumatology, 
Amiens University Hospital, Amiens, France); E. Hachulla (Pierre Yves Hatron, Internal Medicine, Lille University 
Hospital, Lille, France); C. Larroche (Internal Medicine, Avicenne Hospital, Assistance Publique des Hôpitaux de 
Paris, Bobigny, France); V. Le Guern, X. Puéchal (Internal Medicine, Cochin Hospital, Assistance Publique des 
Hôpitaux de Paris, Paris, France); J. Morel (Rheumatology, Montpellier University Hospital, Montpellier, France);  
A. Perdriger (Rheumatology, Rennes University Hospital, Rennes, France); S. Rist, Rheumatology, Orléans Hospital, 
Orléans, France; O. Vittecoq (Rheumatology, Rouen University Hospital, Rouen, France); P. Ravaud (Centre of 
Clinical Epidemiology, Hotel Dieu Hospital, Assistance Publique des Hôpitaux de Paris, Institut National de la Santé 
et de la Recherche Médicale U378, University of Paris Descartes, Faculty of Medicine, Paris, France). 
 
c) Members of the Spanish GEAS Cohort (SS Study Group, Autoimmune Diseases Study Group GEAS, Spanish 
Society of Internal Medicine SEMI):  
B. Díaz-López (Department of Internal Medicine, Hospital Universitario Central de Asturias, Oviedo), A. Casanovas, 
(Department of Internal Medicine, Hospital Parc Taulí, Sabadell), L. Pallarés (Department of Internal Medicine, 
Hospital Son Espases, Palma de Mallorca), M. López-Dupla (Department of Internal Medicine, Hospital Joan XXIII, 
Tarragona), R. Pérez-Alvarez (Department of Internal Medicine, Hospital do Meixoeiro, Vigo), M. Ripoll (Department 
of Internal Medicine, Hospital Infanta Sofía, Madrid), B. Pinilla (Department of Internal Medicine, Hospital Gregorio 
16 
 
Marañón, Madrid), M. Akasbi (Department of Internal Medicine, Hospital Infanta Leonor, Madrid), B. Maure 
(Department of Internal Medicine, Complejo Hospitalario Universitario, Vigo), E. Fonseca (Department of Internal 
Medicine, Hospital de Cabueñes, Gijón), J. Canora (Department of Internal Medicine, Hospital Universitario de 
Fuenlabrada, Madrid), G de la Red (Department of Internal Medicine, Hospital Espíritu Santo, Barcelona), A.J. 
Chamorro (Department of Internal Medicine, Complejo Hospitalario de Ourense, Ourense), I. Jiménez-Heredia 
(Department of Internal Medicine, Hospital de Manises, Valencia, Spain), P. Fanlo (Complejo Universitario de 
Navarra), P. Guisado-Vasco (Hospital Quirón, Madrid), M. Zamora (Hospital Virgen de las Nieves, Granada). 
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TABLE 1. Baseline characteristics of 8310 patients with primary SjS 
Variable Patients (%) 
Gender (Female) 7748 (93.2) 
Age at diagnosis (n = 8270) 53.2 ± 14.2 
Dry eye 7660 (92.2) 
Dry mouth 7700 (92.7) 
Abnormal ocular tests 6228/7273 (85.6) 
   Schirmer's test 4903/6203 (79.0) 
   Rose bengal score or other ocular dye score 2460/3302 (74.5) 
Positive minor salivary gland biopsy 5305/5984 (88.7) 
Abnormal oral diagnostic tests 4843/6063 (79.9) 
   Unstimulated whole salivary flow 3608/4938 (73.1) 
   Parotid sialography 702/873 (80.4) 
   Salivary scintigraphy 2160/2578 (83.8) 
Positive anti-Ro/La antibodies 6177/8250 (74.9) 
   Anti-Ro antibodies 5950/8245 (72.2) 
   Anti-La antibodies 3599/8215 (43.8) 
ANA positive 6292/7746 (81.2) 
RF positive 3483/7154 (48.7) 
C3 low 912/6554 (13.9) 
C4 low 846/6540 (12.9) 
Positive cryoglobulins 307/4118 (7.5) 
Ethnicity  
   White 6174/7884 (78.3) 
   Asian 1066/7884 (13.5) 
   Hispanic 393/7884 (5.0) 
   Black/African American 104/7884 (1.3) 
   Others 147/7884 (1.9) 
Geolocation  
   Europe 6045 (72.7) 
      North (>50ºN) 1393 (16.7) 
      South (<50ºN )   4652 (56.0) 
   America 1134 (13.6) 
      North (>0º) 881 (10.6) 
      South (<0º) 253 (3.0) 
   Asia 940 (11.3) 
      North (>30ºN) 300 (3.6) 
      South (<30ºN) 640 (7.7) 
   Africa 45 (0.6) 
   Australia 146 (1.8) 
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TABLE 2. Features at diagnosis according to geolocation. 
Variable 
EUROPE  AMERICA  ASIA 
North (>50ºN)      
(n = 1393) 
South (<50ºN) 
(n = 4652) 
P-value†  
North (>0º)          
(n = 881) 
South (<0º)         
(n = 253) 
P-value‡  
North (>30ºN)     
(n = 640) 
South (<30ºN)     
(n = 300) 
P-value§ 
Gender (Female) 1286 (92.3) 4311 (92.7) 0.741  821 (93.2) 247 (97.6) 0.022  623 (97.3) 287 (95.7) 0.366 
Age at diagnosis 54 ± 14.7 54 ± 14 0.997  53.9 ± 14.1 50 ± 12.6 <0.001  50.2 + 14.1 43.7 ± 10.4 <0.001 
Dry eye 1251 (89.8) 4414 (94.9) <0.001  856 (97.2) 247 (97.6) 0.951  428 (66.9) 275 (91.7) <0.001 
Dry mouth 1309 (94) 4322 (92.9) 0.250  867 (98.4) 243 (96) 0.057  496 (77.5) 276 (92) <0.001 
Abnormal ocular tests 933/1175 (79.4) 3519/4024 (87.5) <0.001  664/780 (85.1) 199/243 (81.9) 0.333  514/608 (84.5) 244/266 (91.7) 0.011 
   Schirmer's test 884/1171 (75.5) 2483/2972 (83.5) <0.001  499/774 (64.5) 190/243 (78.2) <0.001  452/601 (75.2) 244/266 (91.7) <0.001 
   Rose bengal/other ocular dye score 269/479 (56.2) 1436/1703 (84.3) <0.001  431/660 (65.3) 77/97 (79.4) 0.018  237/350 (67.7) NP NA 
Positive minor salivary gland biopsy 1092/1199 (91.1) 2864/3221 (88.9) 0.061  559/655 (85.3) 176/185 (95.1) 0.002  282/353 (79.9) 244/270 (90.4) 0.001 
Abnormal oral diagnostic tests 893/1007 (88.7) 2602/3365 (77.3) <0.001  566/760 (74.5) 205/243 (84.4) 0.005  494/596 (82.9) 3/3 (100) 1 
   Unstimulated whole salivary flow 861/995 (86.5) 1573/2382 (66) <0.001  547/748 (73.1) 185/232 (79.7) 0.070  375/494 (75.9) NP NA 
   Parotid sialography 41/47 (87.2) 606/738 (82.1) 0.572  29/33 (87.9) 1/1 (100) 1  10/17 (58.8) 1/1 (100) 1 
   Salivary scintigraphy 210/224 (93.8) 1657/2019 (82.1) <0.001  23/27 (85.2) 70/80 (87.5) 1  169/181 (93.4) 2/2 (100) 1 
Positive anti-Ro/La antibodies 955/1387 (68.9) 3470/4640 (74.8) <0.001  679/880 (77.2) 138/246 (56.1) <0.001  572/633 (90.4) 216/280 (77.1) <0.001 
   Anti-Ro antibodies 946/1386 (68.3) 3328/4637 (71.8) 0.019  631/879 (71.8) 136/246 (55.3) <0.001  550/633 (86.9) 215/280 (76.8) 0.001 
   Anti-La antibodies 598/1379 (43.4) 1974/4625 (42.7) 0.741  406/880 (46.1) 60/246 (24.4) <0.001  317/628 (50.5) 131/274 (47.8) 0.651 
ANA positive 1020/1334 (76.5) 3528/4259 (82.8) <0.001  672/848 (79.2) 179/248 (72.2) 0.039  555/601 (92.3) 216/284 (76.1) <0.001 
RF positive 652/1094 (59.6) 1931/4086 (47.3) <0.001  368/834 (44.1) 88/252 (34.9) 0.022  295/595 (49.6) 135/248 (54.4) 0.366 
C3 low 148/806 (18.4) 546/3798 (14.4) 0.008  31/728 (4.3) 8/252 (3.2) 0.668  132/601 (22) 35/212 (16.5) 0.201 
C4 low 116/741 (15.7) 547/3850 (14.2) 0.416  78/726 (10.7) 6/252 (2.4) <0.001  60/602 (10) 17/212 (8) 0.651 
Positive cryoglobulins 36/237 (15.2) 262/3449 (7.6) <0.001  3/42 (7.1) 0/108 (0) 0.048  2/124 (1.6) 0/94 (0) 0.724 
Adjusted p-values for sixty comparisons with false discovery rate (FDR) correction corresponding to the comparison of European (†), American (‡) and Asian (§) countries.  
NP: Not performed, NA: Not available.  
In bold: Statistically significant (p<0.05) variables associated with geolocation in the multivariable logistic regression analysis adjusted for ethnicity, age at diagnosis and gender. 
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TABLE 3. Features at diagnosis according to ethnicity groups. 
 
Variable 
White                         
(n = 6174) 
Asian                          
(n = 1066) 
Hispanic                       
(n = 393) 
Black/African 
American (n = 104) 
Others                         
(n = 147) 
Gender (Female) 5720 (92.6) 1028 (96.4) 372 (94.7) 91 (87.5) 141 (95.9) 
Age at diagnosis 54.2 ± 14.2 48.3 ± 13.3 47.8 ± 12.9 47.2 ± 12.4 52.5 ± 13.7 
Dry eye 5826 (94.4) 817 (76.6) 376 (95.7) 97 (93.3) 144 (98) 
Dry mouth 5775 (93.5) 891 (83.6) 378 (96.2) 99 (95.2) 146 (99.3) 
Abnormal ocular tests 4656/5354 (87) 818/953 (85.8) 334/373 (89.5) 65/78 (83.3) 115/146 (78.8) 
   Schirmer's test 3525/4351 (81) 746/940 (79.4) 301/345 (87.2) 33/52 (63.5) 59/146 (40.4) 
   Rose bengal score or other ocular dye score 1949/2564 (76) 261/387 (67.4) 132/175 (75.4) 20/30 (66.7) 95/140 (67.9) 
Positive minor salivary gland biopsy 3943/4406 (89.5) 592/709 (83.5) 258/272 (94.9) 66/81 (81.5) 103/138 (74.6) 
Abnormal oral diagnostic tests 3664/4504 (81.3) 555/679 (81.7) 301/330 (91.2) 42/63 (66.7) 93/144 (64.6) 
   Unstimulated whole salivary flow 2625/3546 (74) 430/571 (75.3) 253/292 (86.6) 35/58 (60.3) 93/144 (64.6) 
   Parotid sialography¶ 655/813 (80.6) 14/22 (63.6) 31/35 (88.6) 1/2 (50) NP 
   Salivary scintigraphy¶ 1880/2262 (83.1) 179/194 (92.3) 74/89 (83.1) 12/14 (85.7) NP 
Positive anti-Ro/La antibodies 4524/6154 (73.5) 896/1039 (86.2) 308/389 (79.2) 81/102 (79.4) 90/147 (61.2) 
   Anti-Ro antibodies 4347/6152 (70.7) 873/1039 (84) 299/387 (77.3) 79/101 (78.2) 80/147 (54.4) 
   Anti-La antibodies 2669/6130 (43.5) 510/1027 (49.7) 180/390 (46.2) 40/102 (39.2) 41/147 (27.9) 
ANA positive 4877/6062 (80.5) 876/1006 (87.1) 291/381 (76.4) 87/104 (83.7) 117/145 (80.7) 
RF positive 2695/5549 (48.6) 488/954 (51.2) 202/384 (52.6) 49/97 (50.5) 39/145 (26.9) 
C3 low 684/5069 (13.5) 182/901 (20.2) 36/337 (10.7) 9/82 (11) 0/144 (0) 
C4 low 685/5064 (13.5) 91/901 (10.1) 51/333 (15.3) 10/77 (13) 8/144 (5.6) 
Positive cryoglobulins 296/3664 (8.1) 3/266 (1.1) 4/128 (3.1) 3/52 (5.8) 0/1 (0) 
*All comparisons were statistically significant (adjusted p-values for twenty comparisons with false discovery rate (FDR) correction < 0.05) except for parotid 
sialography with a p-value equal to 0.086. 
NP: Not performed. 
¶ P-value was computed excluding Others.  
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FIGURE LEGENDS 
Figure 1. Cluster bar charts for the % of fulfilment of the 6 items of the 2002 
classification criteria according to ethnicity. 
Figure 2. Cluster bar charts for the % of abnormal results in the immunological profile 
according to ethnicity. 
Supplementary Figure S1. Missing data pattern. 
Supplementary Figure S2. Cluster bar charts for the % of fulfilment of the 6 items of 
the 2002 classification criteria of A) Asian patients diagnosed in non-Asian countries 
compared with B) native patients. 
Supplementary Figure S3. Cluster bar charts for the % of abnormal results in the 
immunological profile of A) Hispanic patients diagnosed in non-Latin American 
countries compared with B) native patients. 
Supplementary Figure S4. Size of each cohort classified per city. 
Supplementary Figure S5. Correlation between the percentage of biopsied patients 
and the percentage of Ro/La positive patients in each center. 
 
 
